Live
FierceBiotechModerna’s flu candidate sails through FDA advisory committee in unanimous votesEndpoints NewsFDA vaccine advisors unanimously support Moderna's flu shotScienceWolves are reconquering Europe. Can people learn to live with them?Clinical OMICsPakistan’s Massive Genetic Database Reveals Millions of Unique VariantsClinical OMICsFirst Novel Antifungal for Aspergillus in 20 Years Succeeds in Phase IIIBioWorldMoney raised by biopharmaBioWorldBiopharma money raised: Jan. 1-June 18, 2026Endpoints NewsTreasury weighs screening investments in China biotechBioPharma DivecAMPfield lands $180M to build gut disease drugEndpoints NewsNovo Nordisk expands in China and Czech; Cellares boosts Series D by $50MBioPharma DiveBiogen adds more immune drugs in $1B buyout of secretive startup RaytheraPromega BlogWhat Happens When You Delay an Ebola Vaccine Booster by 18 Months?
FierceBiotech Jan 22, 2026

Hoth strikes back against cancer drug skin toxicities, but share price stays frozen

Hoth strikes back against cancer drug skin toxicities, but share price stays frozen

Original
Body unavailable. Use the original source.